[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522784":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":19,"locations":29,"responsibleParty":66,"collaborators":7,"id":68,"slug":7,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":7,"enrollmentInfo":77,"targetDuration":7,"studyType":80,"phases":7,"briefSummary":81,"conditions":82,"keywords":88,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Gene Solutions","INDUSTRY",null,[9,13,16],{"name":10,"affiliation":11,"role":12},"Sinh D Nguyen, PHD","MGI","PRINCIPAL_INVESTIGATOR",{"name":14,"affiliation":15,"role":12},"Trung Q Lam, MD","University medical center HCMC",{"name":17,"affiliation":18,"role":12},"Samuel J Haryono, MD","MRCCC Siloam Hospitals Semanggi",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Lan NL Tu, PHD","CONTACT","+84888843489","lantu@genesolutions.vn",{"name":26,"role":22,"phone":27,"phoneExt":7,"email":28},"Van T. Phan, MSc","+84908145990","vanphan@genesolutions.vn",[30,44,58],{"facility":18,"status":31,"city":32,"state":7,"zip":7,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Jakarta","Indonesia",{"type":35,"coordinates":36},"Point",[37,38],106.84513,-6.21462,{"lat":38,"lon":37},[41],{"name":17,"role":22,"phone":42,"phoneExt":7,"email":43},"(+62) 021 56967525","samuelharyono@dharmaissurgonc.com",{"facility":45,"status":31,"city":46,"state":7,"zip":7,"country":47,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"Medical Genetics Institute","Ho Chi Minh City","Vietnam",{"type":35,"coordinates":49},[50,51],106.62965,10.82302,{"lat":51,"lon":50},[54,56],{"name":55,"role":22,"phone":23,"phoneExt":7,"email":24},"Lan NL Tu, PhD",{"name":57,"role":12,"phone":7,"phoneExt":7,"email":7},"Sinh D. Nguyen, PhD. MD",{"facility":59,"status":31,"city":46,"state":7,"zip":7,"country":47,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},"University Medical Center HCMC",{"type":35,"coordinates":61},[50,51],{"lat":51,"lon":50},[64,65],{"name":14,"role":22,"phone":7,"phoneExt":7,"email":7},{"name":14,"role":12,"phone":7,"phoneExt":7,"email":7},{"type":67,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100522784",false,"NCT06087120","Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment","Investigate the Prognostic and Predictive Value of Circulating Tumor DNA (ctDNA) During Neoadjuvant Chemotherapy for Breast Cancer.","BRAVA","Inclusion Criteria:\n\n* Female,18 years old and older,\n* Are diagnosed with stage II-III HER2+\u002FTriple Negative breast cancer and indicated for neoadjuvant chemotherapy,\n* FFPE sample is available at the time of diagnosis and operation,\n* Are voluntary to participate in the study.\n\nExclusion Criteria:\n\n* Recurrent breast cancer,\n* Other cancer metastasis to the breast,\n* Have been or are being treated for cancer,\n* Patients did not agree to participate in the studies.","FEMALE","18 Years",{"count":78,"type":79},125,"ESTIMATED","OBSERVATIONAL","This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.\n\n* Determine the rate of ctDNA positivity at the time before treatment,\n* Determine the rate of ctDNA positivity at the time during treatment,\n* Determine the rate of ctDNA positivity at the time after neoadjuvant therapy, whether there is a change in ctDNA expression of the study population during treatment.\n\nAnd aiming to investigate the relationship between ctDNA expression and MRI imaging with pCR response in neo-adjuvant therapy:\n\n* Correlation between ctDNA detection and pCR response. Determine the percentage of Positive Prediction Value - PPV, Negative Prediction Value - NPV of ctDNA,\n* Correlation between MRI imaging and pCR response. Determination of PPV, NPV of MRI\n* Combination of ctDNA detection and MRI imaging in the prognosis of pCR. Determination of PPV, NPV ratio of ctDNA combined with MRI.",[83,84,85,86,87],"Breast Cancer Female","Stage II Breast Cancer","Stage III Breast Cancer","HER2-positive Breast Cancer","Triple Negative Breast Cancer",[89,90,47,33],"Liquid Biopsy","Circulating Tumour DNA","2025-09-18",{"date":93,"type":94},"2025-09-23","ACTUAL",{"date":96,"type":94},"2023-09-16",{"date":98,"type":79},"2025-12-31",{"name":5,"class":6},3]